KYORIN Pharmaceutical Co.,Ltd. (4569.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	126.3B	126.3B	130.1B	119.5B	113.3B
Cost of Revenue	17.0B	74.6B	70.6B	68.1B	63.1B
Gross Profit	13.3B	51.6B	59.5B	51.4B	50.2B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	10.9B	48.1B	47.0B	45.4B	45.0B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	10.9B	48.1B	47.0B	45.4B	45.0B
Cost and Expenses	122.7B	122.7B	117.5B	113.5B	108.1B
Operating Income (EBIT)	3.6B	3.6B	12.6B	6.0B	5.1B
Non-Operating
Interest Income	—	17.0M	1.0M	41.0M	19.0M
Interest Expense	64.0M	254.0M	173.0M	66.0M	66.0M
Net Interest Income	(64.0M)	(237.0M)	(172.0M)	(25.0M)	(47.0M)
Other Non-Op Income/Expense	255.0M	463.0M	652.0M	589.0M	705.0M
Non-Operating Income (excl Interest)	326.0M	795.0M	869.0M	694.0M	780.0M
EBT (Pre-Tax Income)	2.7B	4.5B	12.8B	7.0B	6.9B
Income Tax Expense	628.0M	1.0B	3.7B	1.7B	2.2B
Bottom Line
Net Income	3.4B	3.4B	9.1B	5.3B	4.7B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	3.4B	3.4B	9.1B	5.3B	4.7B
Per Share
Basic EPS	¥60	¥60	¥158	¥93	¥82
Diluted EPS	¥60	¥60	—	—	—
Revenue Per Share	¥2,198	¥2,198	¥2,264	¥2,083	¥1,977
Shares
Basic Shares Outstanding	57.4M	57.4M	57.4M	57.4M	57.3M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	8.2B	17.2B	10.3B	9.0B
D&A	—	4.7B	4.6B	4.3B	3.8B
EBIT	3.6B	3.6B	12.6B	6.0B	5.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026